|
Gene: CCDC84 |
Gene summary for CCDC84 |
Gene summary. |
Gene information | Species | Human | Gene symbol | CCDC84 | Gene ID | 338657 |
Gene name | centrosomal AT-AC splicing factor | |
Gene Alias | CCDC84 | |
Cytomap | 11q23.3 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q86UT8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
338657 | CCDC84 | male-WTA | Human | Thyroid | PTC | 9.82e-13 | 1.56e-01 | 0.1037 |
338657 | CCDC84 | PTC01 | Human | Thyroid | PTC | 6.97e-08 | 1.16e-01 | 0.1899 |
338657 | CCDC84 | PTC03 | Human | Thyroid | PTC | 9.06e-06 | 2.25e-01 | 0.1784 |
338657 | CCDC84 | PTC04 | Human | Thyroid | PTC | 2.64e-26 | 3.19e-01 | 0.1927 |
338657 | CCDC84 | PTC05 | Human | Thyroid | PTC | 3.33e-13 | 6.12e-01 | 0.2065 |
338657 | CCDC84 | PTC06 | Human | Thyroid | PTC | 1.02e-14 | 4.01e-01 | 0.2057 |
338657 | CCDC84 | PTC07 | Human | Thyroid | PTC | 2.03e-14 | 2.90e-01 | 0.2044 |
338657 | CCDC84 | ATC09 | Human | Thyroid | ATC | 8.03e-11 | 3.69e-01 | 0.2871 |
338657 | CCDC84 | ATC12 | Human | Thyroid | ATC | 1.93e-17 | 2.47e-01 | 0.34 |
338657 | CCDC84 | ATC13 | Human | Thyroid | ATC | 1.96e-15 | 2.09e-01 | 0.34 |
338657 | CCDC84 | ATC1 | Human | Thyroid | ATC | 7.96e-09 | 3.78e-01 | 0.2878 |
338657 | CCDC84 | ATC2 | Human | Thyroid | ATC | 8.86e-10 | 6.72e-01 | 0.34 |
338657 | CCDC84 | ATC4 | Human | Thyroid | ATC | 7.42e-18 | 3.55e-01 | 0.34 |
338657 | CCDC84 | ATC5 | Human | Thyroid | ATC | 1.71e-22 | 2.37e-01 | 0.34 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ATC: Anaplastic thyroid cancer | |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CCDC84 | SNV | Missense_Mutation | c.796N>G | p.Leu266Val | p.L266V | Q86UT8 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-E2-A159-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
CCDC84 | SNV | Missense_Mutation | rs782494985 | c.185N>A | p.Arg62Gln | p.R62Q | Q86UT8 | protein_coding | tolerated(0.59) | benign(0.003) | TCGA-DS-A7WH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CCDC84 | SNV | Missense_Mutation | novel | c.811N>C | p.Lys271Gln | p.K271Q | Q86UT8 | protein_coding | tolerated(0.35) | benign(0.035) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
CCDC84 | SNV | Missense_Mutation | c.899N>C | p.Phe300Ser | p.F300S | Q86UT8 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EI-6506-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CCDC84 | SNV | Missense_Mutation | c.551N>T | p.Ala184Val | p.A184V | Q86UT8 | protein_coding | tolerated(0.16) | benign(0.003) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CCDC84 | SNV | Missense_Mutation | novel | c.793N>G | p.Phe265Val | p.F265V | Q86UT8 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CCDC84 | SNV | Missense_Mutation | novel | c.514N>T | p.Pro172Ser | p.P172S | Q86UT8 | protein_coding | tolerated(0.32) | benign(0.011) | TCGA-A5-A2K7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD |
CCDC84 | SNV | Missense_Mutation | c.351G>T | p.Glu117Asp | p.E117D | Q86UT8 | protein_coding | tolerated(0.54) | benign(0.011) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
CCDC84 | SNV | Missense_Mutation | novel | c.838N>T | p.Asp280Tyr | p.D280Y | Q86UT8 | protein_coding | deleterious(0.01) | possibly_damaging(0.748) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
CCDC84 | SNV | Missense_Mutation | rs782437414 | c.790G>A | p.Glu264Lys | p.E264K | Q86UT8 | protein_coding | deleterious(0.01) | possibly_damaging(0.54) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |